€25.70
0.76% yesterday
L&S, Jul 03, 10:55 pm CET
ISIN
US7170811035
Symbol
PFE
Sector
Industry

Pfizer Share price

$27.70
-1.61 5.49% 1M
-2.03 6.83% 6M
-1.09 3.79% YTD
-8.95 24.42% 1Y
-12.03 30.28% 3Y
-14.36 34.14% 5Y
-1.22 4.22% 10Y
NYSE, Closing price Wed, Jul 03 2024
-0.13 0.47%
ISIN
US7170811035
Symbol
PFE
Sector
Industry

Key metrics

Market capitalization $156.96b
Enterprise Value $214.85b
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 42.08
EV/Sales (TTM) EV/Sales 3.90
P/S ratio (TTM) P/S ratio 2.85
P/B ratio (TTM) P/B ratio 1.70
Dividend yield 5.93%
Last dividend (FY23) $1.65
Sales growth (TTM) Sales growth -40.73%
Turnover (TTM) Turnover $55.09b
EBIT (operating result TTM) EBIT $1.78b
Free cash flow (TTM) Free cash flow $5.11b
Cash position $11.93b
EPS (TTM) EPS $-0.06
P/E ratio expected 16.70
P/S ratio expected 2.59
EV/Sales expected 3.55
Short interest 1.10%
Show more

Is Pfizer a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.

Pfizer Share analysis

Unlock Scores for Free

Analyst opinions

26 Analysts have issued a Pfizer forecast:

9x Buy
35%
17x Hold
65%

Analyst opinions

26 Analysts have issued a Pfizer forecast:

Buy
35%
Hold
65%

Financial data from Pfizer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '24
+/-
%
55,094 55,094
41% 41%
100%
- Direct costs 28,171 28,171
15% 15%
51%
26,923 26,923
55% 55%
49%
- Selling and administrative expenses 8,041 8,041
6% 6%
15%
- Research and development costs 10,564 10,564
9% 9%
19%
8,318 8,318
79% 79%
15%
- Depreciation and amortization 6,539 6,539
22% 22%
12%
EBIT (operating result) EBIT 1,779 1,779
95% 95%
3%
Net profit -289 -289
101% 101%
-1%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Pfizer share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Pfizer Share News

Positive
InvestorPlace
about 13 hours ago
When it rains, it pours. However, the storm will eventually pass.
Neutral
MarketBeat
one day ago
Pharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender.
Negative
The Motley Fool
one day ago
Pfizer is in the midst of transition as it faces multiple patent cliffs. The company's growth strategy suggests that the business could be bigger by the end of the decade, but not necessarily by a whole lot.
More Pfizer News

Company profile

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Head office United States
CEO Albert Bourla
Employees 88,000
Founded 1849
Website www.pfizer.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today